[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 5 of about 5
1. Radvanyi L, Singh-Sandhu D, Gallichan S, Lovitt C, Pedyczak A, Mallo G, Gish K, Kwok K, Hanna W, Zubovits J, Armes J, Venter D, Hakimi J, Shortreed J, Donovan M, Parrington M, Dunn P, Oomen R, Tartaglia J, Berinstein NL: The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. Proc Natl Acad Sci U S A; 2005 Aug 2;102(31):11005-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer.
  • A comprehensive differential gene expression screen on a panel of 54 breast tumors and >200 normal tissue samples using DNA microarrays revealed 15 genes specifically overexpressed in breast cancer.
  • One of the most prevalent genes found was trichorhinophalangeal syndrome type 1 (TRPS-1), a gene previously shown to be associated with three rare autosomal dominant genetic disorders known as the trichorhinophalangeal syndromes.
  • A number of corroborating methodologies, including in situ hybridization, e-Northern analysis using ORF EST (ORESTES) and Unigene EST abundance analysis, immunoblot and immunofluorescence analysis of breast tumor cell lines, and immunohistochemistry, confirmed the microarray findings.
  • Immunohistochemistry analysis found TRPS-1 protein expressed in >90% of early- and late-stage breast cancer, including ductal carcinoma in situ and invasive ductal, lobular, and papillary carcinomas.
  • [MeSH-major] Breast Neoplasms / genetics. DNA-Binding Proteins / genetics. Langer-Giedion Syndrome / genetics. Neoplasm Proteins / genetics
  • [MeSH-minor] Amino Acid Sequence. Animals. Antigens, Neoplasm / genetics. Antigens, Neoplasm / metabolism. Cell Line, Tumor. DNA, Neoplasm / genetics. Epitopes / genetics. Epitopes / metabolism. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Mice. Mice, Transgenic. Molecular Sequence Data. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. T-Lymphocytes / immunology. Transcription Factors

  • Genetic Alliance. consumer health - Trichorhinophalangeal Syndrome.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med Genet. 2002 Jan 1;107(1):26-9 [11807863.001]
  • [Cites] Apoptosis. 2002 Feb;7(1):13-21 [11773701.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1134-8 [11861394.001]
  • [Cites] Development. 2002 May;129(9):2233-46 [11959831.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2736-40 [12019145.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1223-33 [12368196.001]
  • [Cites] J Mol Endocrinol. 2002 Oct;29(2):175-92 [12370120.001]
  • [Cites] Mol Cell Biol. 2002 Dec;22(24):8592-600 [12446778.001]
  • [Cites] Cancer Immun. 2002 Jun 28;2:5 [12747750.001]
  • [Cites] Drug News Perspect. 2003 Jul-Aug;16(6):395-8 [12973450.001]
  • [Cites] J Biol Chem. 2003 Oct 3;278(40):38780-5 [12885770.001]
  • [Cites] Int J Cancer. 1999 Apr 20;84(2):122-8 [10096242.001]
  • [Cites] Nat Genet. 2000 Jan;24(1):71-4 [10615131.001]
  • [Cites] Genome Res. 2000 Apr;10(4):516-22 [10779491.001]
  • [Cites] Breast J. 2003 Nov-Dec;9(6):485-90 [14616943.001]
  • [Cites] Eur J Hum Genet. 2004 Feb;12(2):121-6 [14560312.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Br J Cancer. 2004 Mar 8;90(5):1041-6 [14997205.001]
  • [Cites] N Engl J Med. 2004 Mar 11;350(11):1081-92 [15014181.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):1943-8 [15041710.001]
  • [Cites] J Biol Chem. 2004 May 7;279(19):20154-66 [14769789.001]
  • [Cites] Steroids. 1975 Apr;25(4):497-505 [165596.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Dec;84(24):9243-7 [3321071.001]
  • [Cites] Eur J Immunol. 1992 Sep;22(9):2453-6 [1516632.001]
  • [Cites] J Immunol. 1994 Jan 1;152(1):163-75 [8254189.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):860-5 [8631025.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):4075-81 [9307296.001]
  • [Cites] Mol Cell Biol. 1998 May;18(5):2901-11 [9566909.001]
  • [Cites] Nat Biotechnol. 1996 Dec;14(13):1675-80 [9634850.001]
  • [Cites] J Immunol. 2000 Sep 1;165(5):2341-53 [10946256.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 6;92(17):1414-21 [10974077.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):38949-52 [11042222.001]
  • [Cites] Am J Hum Genet. 2001 Jan;68(1):81-91 [11112658.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2055-61 [11280766.001]
  • [Cites] Nucleic Acids Res. 2002 Jan 1;30(1):17-20 [11752243.001]
  • [Cites] Development. 2002 Feb;129(3):747-59 [11830574.001]
  • (PMID = 16043716.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / Epitopes; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / TRPS1 protein, human; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC1182410
  •  go-up   go-down


2. Sullivan PS, Apple SK: Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma? Breast J; 2009 Mar-Apr;15(2):146-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma?
  • Neoadjuvant chemotherapy is becoming the standard of care in locally advanced breast cancers.
  • We retrospectively identified 49 cases of invasive breast carcinoma treated with neoadjuvant chemotherapy (40 ductal, nine lobular) and examined histologic and biologic features of ductal and lobular carcinoma before and after chemotherapy.
  • Patients with lobular carcinomas presented at a later age and had lower grade tumors that were more likely estrogen and progesterone receptor positive.
  • Ductal carcinomas had a greater frequency of HER-2/neu amplification and increased Ki-67 rate.
  • After chemotherapy, none of the lobular carcinomas had complete pathologic response compared with 28% of the ductal carcinomas (p = 0.01).
  • Lobular carcinomas had more lymph node metastases.
  • At the time of clinical follow-up, no lobular carcinomas had evidence of disease.
  • Only one lobular carcinoma case had any histologic changes after chemotherapy compared with 37-68% of ductal carcinomas (p < 0.05).
  • In ductal carcinomas, higher grade and negative estrogen receptor expression before chemotherapy and presence of foam cell clusters, HER-2/neu expression, and absence of lymphatic or vascular space invasion after chemotherapy correlated with pathologic response (p < 0.05).
  • Breast biomarker status changed in 9% of all lobular carcinomas and 19% of all ductal carcinomas.
  • Lobular carcinomas respond poorly to neoadjuvant chemotherapy as evidence by lack of complete pathologic response and rare histologic tissue response.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Chemotherapy, Adjuvant / methods
  • [MeSH-minor] Adult. Aged. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / pathology. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Middle Aged. Neoplasm Invasiveness. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Retrospective Studies. Tumor Suppressor Protein p53 / analysis


3. Sardanelli F, Iozzelli A, Fausto A, Carriero A, Kirchin MA: Gadobenate dimeglumine-enhanced MR imaging breast vascular maps: association between invasive cancer and ipsilateral increased vascularity. Radiology; 2005 Jun;235(3):791-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gadobenate dimeglumine-enhanced MR imaging breast vascular maps: association between invasive cancer and ipsilateral increased vascularity.
  • PURPOSE: To retrospectively compare three different doses of gadobenate dimeglumine with a standard dose of gadopentetate dimeglumine for magnetic resonance (MR) imaging evaluation of breast vessels and to evaluate the accuracy of one-sided increased vascularity seen on gadobenate dimeglumine-enhanced MR images as an indicator of ipsilateral breast cancer.
  • Ninety-five patients known to have or suspected of having breast cancer were randomly assigned to four groups to receive gadobenate dimeglumine at a dose of 0.05, 0.10, or 0.20 mmol per kilogram of body weight or gadopentetate dimeglumine at a dose of 0.10 mmol/kg.
  • Two readers blinded to the type and dose of contrast agent administered scored the MIPs obtained in the dose groups for vessel number, length, and conspicuity from 0, which indicated absent or low breast vascularity, to 3, which indicated high breast vascularity.
  • Histopathologic analysis revealed malignant lesions in 52 of 69 patients examined with gadobenate dimeglumine MR imaging: invasive ductal carcinoma in 45, invasive lobular carcinoma in four, and invasive mixed ductal-lobular carcinoma in three patients.
  • Two cases of bilateral invasive cancer with symmetric breast vascular maps were excluded.
  • CONCLUSION: Gadobenate dimeglumine is effective for MR imaging evaluation of breast vessels at doses as low as 0.05 mmol/kg.
  • One-sided increased vascularity is an MR imaging finding frequently associated with ipsilateral invasive breast cancer.
  • [MeSH-major] Breast / blood supply. Breast Neoplasms / blood supply. Breast Neoplasms / pathology. Contrast Media. Gadolinium DTPA. Magnetic Resonance Imaging / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright RSNA, 2005
  • [CommentIn] Radiology. 2005 Jun;235(3):717-8 [15914471.001]
  • (PMID = 15845796.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


Advertisement
4. Schneider-Kolsky ME, Hart S, Fox J, Midolo P, Stuckey J, Hofman M, Ganju V: The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET. Breast Cancer Res; 2010;12(3):R37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET.
  • INTRODUCTION: The aims of this study were to investigate whether drug sequence (docetaxel followed by anthracyclines or the drugs in reverse order) affects changes in the maximal standard uptake volume (SUVmax) on [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) during neoadjuvant chemotherapy in women with locally advanced breast cancer.
  • METHODS: Women were randomly assigned to receive either drug sequence, and FDG-PET scans were taken at baseline, after four cycles and after eight cycles of chemotherapy.
  • Thirty-one received docetaxel followed by anthracyclines (Arm A) and 29 received drugs in the reverse order (Arm B).
  • Most women (83%) had ductal carcinoma and 10 women (17%) had lobular or lobular/ductal carcinoma.
  • Overall, there was no significant difference in response between the two drug regimens.
  • CONCLUSIONS: Our results show that SUVmax uptake by breast tumours during chemotherapy can be dependent on the drugs used.
  • Care must be taken when interpreting FDG-PET in settings where patients receive varied drug protocols.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Lobular / diagnosis. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Sci. 2006 Sep;97(9):813-20 [16805818.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2019-27 [16606972.001]
  • [Cites] Oncol Rep. 2007 Jan;17(1):253-9 [17143506.001]
  • [Cites] Breast Cancer Res Treat. 2007 Mar;102(1):75-84 [16897427.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):1915-24 [17579854.001]
  • [Cites] Cancer Biol Ther. 2007 Sep;6(9):1442-8 [17827982.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1573-7 [18552360.001]
  • [Cites] Clin Ter. 2008 Nov-Dec;159(6):453-6 [19169608.001]
  • [Cites] Eur Radiol. 2009 Jun;19(6):1347-57 [19214522.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1551-7 [19326117.001]
  • [Cites] Ann Surg Oncol. 2010 Jan;17(1):247-53 [19777177.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1676-88 [10764428.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1689-95 [10764429.001]
  • [Cites] J Nucl Med. 2002 Apr;43(4):500-9 [11937594.001]
  • [Cites] Cancer Treat Rev. 2003 Oct;29(5):407-15 [12972359.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S103-11 [15103507.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1352-7 [15319241.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 May;130(5):273-8 [14986112.001]
  • [Cites] Radiol Clin North Am. 2004 Nov;42(6):983-1001, vii [15488553.001]
  • [Cites] J Clin Oncol. 1993 Nov;11(11):2101-11 [8229124.001]
  • [Cites] Ultrasound Obstet Gynecol. 1996 Jun;7(6):429-34 [8807760.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):621-6 [9484820.001]
  • [Cites] Cancer J Sci Am. 1998 Mar-Apr;4(2):125-31 [9554929.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2227-34 [9610703.001]
  • [Cites] Am J Surg. 1998 Dec;176(6):502-9 [9926779.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):460-9 [10080586.001]
  • [Cites] Semin Nucl Med. 2005 Apr;35(2):84-99 [15765372.001]
  • [Cites] Oncologist. 2005 Oct;10 Suppl 2:9-17 [16272454.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5366-72 [17088570.001]
  • (PMID = 20565953.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Radiopharmaceuticals; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Taxoids; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 15H5577CQD / docetaxel; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2917032
  •  go-up   go-down


5. Rakha EA, Gill MS, El-Sayed ME, Khan MM, Hodi Z, Blamey RW, Evans AJ, Lee AH, Ellis IO: The biological and clinical characteristics of breast carcinoma with mixed ductal and lobular morphology. Breast Cancer Res Treat; 2009 Mar;114(2):243-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The biological and clinical characteristics of breast carcinoma with mixed ductal and lobular morphology.
  • Although invasive ductal (IDC) and lobular (ILC) breast carcinomas are well characterised in the literature, the biological and clinical significance of mixed tumours with both ductal and lobular components has not been investigated.
  • In the current study, we have examined a well-characterised series of breast carcinoma with a long term follow-up that comprised 140 mixed tumours, 2170 IDC and 380 pure ILC.
  • RESULTS: Mixed tumours constituted 3.6% of all cases.
  • The majority (59%) of the mixed tumours were grade 2 compared to 33% in IDC and 88% in ILC.
  • Positive lymph nodes (LN) were found in 41% and definite vascular invasion (VI) in 26% of the cases.
  • DCIS was detected in 123 (89%) and LCIS in 43 (31%) (both DCIS and LCIS were found in 39 cases).
  • The majority of tumours were predominantly (>50 of tumour area) of ductal type (57%).
  • When compared to pure IDC, mixed tumours showed an association with lower grade, ER positivity and lower frequency of development of distant metastases.
  • When compared to pure ILC, mixed tumours showed an association with higher grade, positive LN metastasis, VI and development of regional metastasis.
  • There was an association between histologic type of carcinoma in LN metastasis and the predominant histologic type of the primary tumour.
  • Mixed tumours showed metastatic patterns similar to that of ILC with frequent metastasis to bone.
  • No clinically meaningful differences in survival were found between these mixed carcinomas and pure IDC or ILC of the breast or between mixed tumours with predominantly ductal or lobular phenotype.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18404368.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down






Advertisement